{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T07:49:55Z","timestamp":1781423395358,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and aims<\/jats:title>\n                <jats:p>People who inject drugs may be particularly vulnerable to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to underlying health problems, stigma and social vulnerabilities. Harm reduction services, including needle exchange programs (NEP), have been subjected to varying degrees of disruption in the world, especially in the beginning of the coronavirus disease 2019 (COVID-19) pandemic. Compared to responses in other countries, Sweden\u2019s initial strategy toward limiting the spread and impact of COVID-19 was less restrictive to its citizens with no imposed general societal lockdown. In this study, we investigate changes in drug use patterns, utilization of NEP associated health services, COVID-19 health literacy and the prevalence of SARS-CoV-2 antibodies among NEP clients in Stockholm during the COVID-19 pandemic.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>NEP visits and services provided (needles\/syringes, HIV and hepatitis C tests and treatment, naloxone distributed) and overall mortality among NEP clients between January 1 and October 31, 2020, were used for trend analyses in comparison with corresponding 2019 data. Between July 27 and October 2, 2020, NEP clients (<jats:italic>n<\/jats:italic>\u2009=\u2009232) responded to a 27 item COVID-19 Health Literacy Questionnaire. SARS CoV-2 IgG antibody tests (<jats:italic>n<\/jats:italic>\u2009=\u2009779) were performed between June 15 and October 31, 2020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the COVID-19 pandemic number of clients, client visits, naloxone distribution and HCV tests remained stable compared to 2019, while distribution of needles\/syringes increased (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001); number of HIV tests and HCV treatments decreased (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05); and mortality decreased (&lt;\u20090.01). Overall, the level of health literacy concerning transmission routes and protective measures was high. SARS-CoV-2 antibody prevalence was 5.4% (95% CI 4.0\u20137.2).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The Stockholm NEP managed to maintain a high level of clients and services during the pandemic. In general, COVID-19 health literacy was adequate and the overall SARS-CoV-2 antibody prevalence was low compared to the general population, which highlights a need for prioritized and targeted COVID-19 vaccination among PWID.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-021-00499-z","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T10:04:29Z","timestamp":1620641069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Health literacy and changes in pattern of drug use among participants at the Stockholm Needle Exchange Program during the COVID-19 pandemic"],"prefix":"10.1186","volume":"18","author":[{"given":"K.","family":"Lindqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wallmofeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Holm\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hammarberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6643-3245","authenticated-orcid":false,"given":"M.","family":"K\u00e5berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"issue":"1","key":"499_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12954-020-00370-7","volume":"17","author":"A Dunlop","year":"2020","unstructured":"Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):26.","journal-title":"Harm Reduct J"},{"issue":"7","key":"499_CR2","doi-asserted-by":"publisher","first-page":"e25583","DOI":"10.1002\/jia2.25583","volume":"23","author":"TI Vasylyeva","year":"2020","unstructured":"Vasylyeva TI, Smyrnov P, Strathdee S, Friedman SR. Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks. J Int AIDS Soc. 2020;23(7):e25583.","journal-title":"J Int AIDS Soc"},{"key":"499_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41380-020-00880-7","volume":"26","author":"QQ Wang","year":"2020","unstructured":"Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2020;26:30\u20139.","journal-title":"Mol Psychiatry"},{"key":"499_CR4","doi-asserted-by":"publisher","first-page":"102851","DOI":"10.1016\/j.drugpo.2020.102851","volume":"83","author":"M Whitfield","year":"2020","unstructured":"Whitfield M, Reed H, Webster J, Hope V. The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England. Int J Drug Policy. 2020;83:102851.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"499_CR5","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1007\/s10461-020-02886-2","volume":"24","author":"SN Glick","year":"2020","unstructured":"Glick SN, Prohaska SM, LaKosky PA, Juarez AM, Corcorran MA, Des Jarlais DC. The impact of COVID-19 on syringe services programs in the United States. AIDS Behav. 2020;24(9):2466\u20138.","journal-title":"AIDS Behav"},{"key":"499_CR6","unstructured":"EMCDDA. European Monitoring Centre for Drugs and Drug Addiction, European Drug Report 2020: Trends and developments. Publications Office of the European Union, Luxembourg; 2020."},{"key":"499_CR7","unstructured":"EMCDDA. European Monitoring Centre for Drugs and Drug Addiction, EMCDDA trendspotter briefing, June 2020, Impact of COVID-19 on patterns of drug use and drugrelated harms in Europe, Publications Office of the European Union, Luxembourg; 2020."},{"issue":"12","key":"499_CR8","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1111\/apa.15582","volume":"109","author":"JF Ludvigsson","year":"2020","unstructured":"Ludvigsson JF. The first eight months of Sweden\u2019s COVID-19 strategy and the key actions and actors that were involved. Acta Paediatr. 2020;109(12):2459\u201371.","journal-title":"Acta Paediatr"},{"issue":"4","key":"499_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.hlpt.2020.08.009","volume":"9","author":"A Kavaliunas","year":"2020","unstructured":"Kavaliunas A, Ocaya P, Mumper J, Lindfeldt I, Kyhlstedt M. Swedish policy analysis for Covid-19. Health Policy Technol. 2020;9(4):598\u2013612.","journal-title":"Health Policy Technol"},{"key":"499_CR10","unstructured":"Folkh\u00e4lsomyndigheten. [The Public Health Agency of Sweden], Notified cases of COVID-19 in Sweden\u2014a daily update. 2020. https:\/\/www.folkhalsomyndigheten.se\/smittskydd-beredskap\/utbrott\/aktuella-utbrott\/covid-19\/statistik-och-analyser\/bekraftade-fall-i-sverige\/. Accessed 15 Nov 2020."},{"key":"499_CR11","unstructured":"Institute of Medicine Committee on Health L. In: Nielsen-Bohlman L, Panzer AM, Kindig DA, editors. Health Literacy: A Prescription to End Confusion. Washington (DC): National Academies Press (US). Copyright 2004 by the National Academy of Sciences. All rights reserved; 2004."},{"key":"499_CR12","unstructured":"WHO. Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva, Switzerland. 2012. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/75357\/9789241504041_eng.pdf;jsessionid=C9828AAD19CA5A28DF7A33C2AFC72430?sequence=1. Accessed 15 Nov 2020."},{"key":"499_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jsat.2018.10.009","volume":"96","author":"TJ Degan","year":"2019","unstructured":"Degan TJ, Kelly PJ, Robinson LD, Deane FP. Health literacy in substance use disorder treatment: a latent profile analysis. J Subst Abuse Treat. 2019;96:46\u201352.","journal-title":"J Subst Abuse Treat"},{"key":"499_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.drugpo.2017.06.001","volume":"47","author":"AD Marshall","year":"2017","unstructured":"Marshall AD, Grebely J, Dore GJ, Treloar C. \u201cI didn\u2019t want to let it go too far.\u201d The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study. Int J Drug Policy . 2017;47:153\u201360.","journal-title":"Int J Drug Policy"},{"key":"499_CR15","doi-asserted-by":"publisher","first-page":"108186","DOI":"10.1016\/j.drugalcdep.2020.108186","volume":"214","author":"D Dahlman","year":"2020","unstructured":"Dahlman D, Ekef\u00e4ll M, Garpenhag L. Health literacy among Swedish patients in opioid substitution treatment: a mixed-methods study. Drug Alcohol Depend. 2020;214:108186.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"499_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1080\/23744235.2017.1334263","volume":"49","author":"M Kaberg","year":"2017","unstructured":"Kaberg M, Hammarberg A, Lidman C, Weiland O. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program. Infect Dis (Lond). 2017;49(10):728\u201336.","journal-title":"Infect Dis (Lond)"},{"key":"499_CR17","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/jvh.12969","volume":"25","author":"M Kaberg","year":"2020","unstructured":"Kaberg M, Naver G, Hammarberg A, Weiland O. Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination. J Viral Hepat. 2020;25:1452\u201361.","journal-title":"J Viral Hepat"},{"issue":"5","key":"499_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/23744235.2020.1727002","volume":"52","author":"M K\u00e5berg","year":"2020","unstructured":"K\u00e5berg M, Karlsson N, Discacciati A, Widgren K, Weiland O, Ekstr\u00f6m AM, et al. Significant decrease in injection risk behaviours among participants in a needle exchange programme. Infect Dis (Lond). 2020;52(5):336\u201346.","journal-title":"Infect Dis (Lond)"},{"key":"499_CR19","doi-asserted-by":"publisher","first-page":"102821","DOI":"10.1016\/j.drugpo.2020.102821","volume":"83","author":"TS Bartholomew","year":"2020","unstructured":"Bartholomew TS, Nakamura N, Metsch LR, Tookes HE. Syringe services program (SSP) operational changes during the COVID-19 global outbreak. Int J Drug Policy. 2020;83:102821.","journal-title":"Int J Drug Policy."},{"issue":"1","key":"499_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12954-020-00432-w","volume":"17","author":"CA Picchio","year":"2020","unstructured":"Picchio CA, Valencia J, Doran J, Swan T, Pastor M, Martr\u00f3 E, et al. The impact of the COVID-19 pandemic on harm reduction services in Spain. Harm Reduct J. 2020;17(1):87.","journal-title":"Harm Reduct J"},{"key":"499_CR21","unstructured":"WHO. Global Health Sector strategy on viral hepatitis 2016\u20132021, towards ending viral hepatitis. Geneva; 2016."},{"key":"499_CR22","unstructured":"WHO. Combating hepatitis B and C to reach elimination to 2030. 2016."},{"key":"499_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2016.06.004","volume":"37","author":"S Brothers","year":"2016","unstructured":"Brothers S. Merchants, samaritans, and public health workers: Secondary syringe exchanger discursive practices. Int J Drug Policy. 2016;37:1\u20138.","journal-title":"Int J Drug Policy"},{"key":"499_CR24","unstructured":"WHO. The World Health Organization, Fact sheet - Alcohol and COVID-19: what you need to know. 2020. https:\/\/www.euro.who.int\/en\/media-centre\/sections\/fact-sheets\/2020\/fact-sheet-alcohol-and-covid-19-what-you-need-to-know-2020. Accessed 15 Nov 2020."},{"key":"499_CR25","doi-asserted-by":"publisher","first-page":"102872","DOI":"10.1016\/j.drugpo.2020.102872","volume":"83","author":"AB Collins","year":"2020","unstructured":"Collins AB, Ndoye CD, Arene-Morley D, Marshall BDL. Addressing co-occurring public health emergencies: the importance of naloxone distribution in the era of COVID-19. Int J Drug Policy. 2020;83:102872.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"499_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/dar.13079","volume":"39","author":"PM Dietze","year":"2020","unstructured":"Dietze PM, Peacock A. Illicit drug use and harms in Australia in the context of COVID-19 and associated restrictions: anticipated consequences and initial responses. Drug Alcohol Rev. 2020;39(4):297\u2013300.","journal-title":"Drug Alcohol Rev"},{"issue":"6","key":"499_CR27","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s11524-020-00484-0","volume":"97","author":"N Glober","year":"2020","unstructured":"Glober N, Mohler G, Huynh P, Arkins T, O\u2019Donnell D, Carter J, et al. Impact of COVID-19 pandemic on drug overdoses in Indianapolis. J Urban Health. 2020;97(6):802\u20137.","journal-title":"J Urban Health"},{"key":"499_CR28","doi-asserted-by":"publisher","first-page":"102896","DOI":"10.1016\/j.drugpo.2020.102896","volume":"83","author":"A Schlosser","year":"2020","unstructured":"Schlosser A, Harris S. Care during COVID-19: Drug use, harm reduction, and intimacy during a global pandemic. Int J Drug Policy. 2020;83:102896.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"499_CR29","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1097\/ADM.0000000000000746","volume":"14","author":"DC Cone","year":"2020","unstructured":"Cone DC, Bogucki S, Burns K, D\u2019Onofrio G, Hawk K, Joseph D, et al. Naloxone use by emergency medical services during the COVID-19 pandemic: a national survey. J Addict Med. 2020;14(6):e369\u201371.","journal-title":"J Addict Med"},{"key":"499_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/10903127.2020.1834656","volume":"25","author":"MJ Glenn","year":"2020","unstructured":"Glenn MJ, Rice AD, Primeau K, Hollen A, Jado I, Hannan P, et al. Refusals after prehospital administration of naloxone during the COVID-19 pandemic. Prehosp Emerg Care. 2020;25:46\u201354.","journal-title":"Prehosp Emerg Care"},{"key":"499_CR31","unstructured":"Socialstyrelsen. [the Swedish Board of Health and Welfare], Information till mottagningar som bedriver l\u00e4kemedelsassisterad behandling vid opioidberoende (LARO) och hur v\u00e5rden kan anpassas f\u00f6r att minska risken f\u00f6r smittspridning p\u00e5 grund av covid-19 [Information to OAT clinics to reducce the spread of COVID-19]. 2020. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/dokument-webb\/ovrigt\/information-laro-covid19.pdf. Accessed 15 Nov 2020."},{"key":"499_CR32","doi-asserted-by":"publisher","first-page":"108176","DOI":"10.1016\/j.drugalcdep.2020.108176","volume":"214","author":"S Slavova","year":"2020","unstructured":"Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214:108176.","journal-title":"Drug Alcohol Depend"},{"key":"499_CR33","doi-asserted-by":"crossref","unstructured":"Friedman J, Beletsky L, Schriger DL. Overdose-related cardiac arrests observed by emergency medical services during the US COVID-19 epidemic. JAMA Psychiatry. 2020.","DOI":"10.1001\/jamapsychiatry.2020.4218"},{"issue":"1","key":"499_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1360-0443.2004.00602.x","volume":"99","author":"A Bartu","year":"2004","unstructured":"Bartu A, Freeman NC, Gawthorne GS, Codde JP, Holman CD. Mortality in a cohort of opiate and amphetamine users in Perth. Western Australia Addiction. 2004;99(1):53\u201360.","journal-title":"Western Australia Addiction"},{"key":"499_CR35","unstructured":"Folkh\u00e4lsomyndigheten. [The Public Health Agency of Sweden], \u00c5tg\u00e4rdsf\u00f6rslag f\u00f6r att f\u00f6rebygga anv\u00e4ndning samt medicinska och sociala skadeverkningar av narkotika [Proposed measures to prevent drug use and medical and social harmful effects of drugs]. 2020. https:\/\/www.folkhalsomyndigheten.se\/contentassets\/5ce3639567ad495eae0dcec6071aaf9e\/atgardsforslag-forebygga-anvandning-medicinska-sociala-skadeverkningar-narkotika.pdf Accessed 15 Nov 2020."},{"issue":"4","key":"499_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1465-3362.2009.00025.x","volume":"28","author":"W Small","year":"2009","unstructured":"Small W, Van Borek N, Fairbairn N, Wood E, Kerr T. Access to health and social services for IDU: the impact of a medically supervised injection facility. Drug Alcohol Rev. 2009;28(4):341\u20136.","journal-title":"Drug Alcohol Rev"},{"issue":"1\u20132","key":"499_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.drugalcdep.2008.05.014","volume":"98","author":"W Small","year":"2008","unstructured":"Small W, Wood E, Lloyd-Smith E, Tyndall M, Kerr T. Accessing care for injection-related infections through a medically supervised injecting facility: a qualitative study. Drug Alcohol Depend. 2008;98(1\u20132):159\u201362.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"499_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.annepidem.2009.03.007","volume":"19","author":"E Lloyd-Smith","year":"2009","unstructured":"Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Determinants of cutaneous injection-related infection care at a supervised injecting facility. Ann Epidemiol. 2009;19(6):404\u20139.","journal-title":"Ann Epidemiol"},{"key":"499_CR39","doi-asserted-by":"publisher","first-page":"102895","DOI":"10.1016\/j.drugpo.2020.102895","volume":"83","author":"BP Jacka","year":"2020","unstructured":"Jacka BP, Phipps E, Marshall BDL. Drug use during a pandemic: Convergent risk of novel coronavirus and invasive bacterial and viral infections among people who use drugs. Int J Drug Policy. 2020;83:102895.","journal-title":"Int J Drug Policy"},{"key":"499_CR40","unstructured":"Folkh\u00e4lsomyndigheten. [The Public Health Agency of Sweden], P\u00e5visning av antikroppar efter genomg\u00e5ngen covid-19 hos blodgivare [Detection of COVID-19 antibodies in blood donors]. 2020. https:\/\/www.folkhalsomyndigheten.se\/contentassets\/376f9021a4c84da08de18ac597284f0c\/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf. Accessed 15 Nov 2020."},{"key":"499_CR41","unstructured":"Folkh\u00e4lsomyndigheten. [The Public Health Agency of Sweden], P\u00e5visning av antikroppar efter genomg\u00e5ngen covid-19 i blodprov fr\u00e5n \u00f6ppenv\u00e5rden [Detection of COVID-19 in blood samples from outpatient care]. 2020. https:\/\/www.folkhalsomyndigheten.se\/contentassets\/9c5893f84bd049e691562b9eeb0ca280\/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf. Accessed 15 Nov 2020."},{"key":"499_CR42","unstructured":"Folkh\u00e4lsomyndigheten. [The Public Health Agency of Sweden], F\u00f6rekomsten av antikroppar mot SARS-CoV-2 i stadsdelsomr\u00e5det Rinkeby- Kista, Stockholm [Presence of antibodies to SARS-CoV-2 in the district area of Rinkeby-Kista, Stockholm]. 2020. https:\/\/www.folkhalsomyndigheten.se\/contentassets\/2cf102cd299c4382b9a0447dc0626356\/forekomsten-antikroppar-rinkeby-kista.pdf. Accessed 15 Nov 2020."},{"key":"499_CR43","unstructured":"EMCDDA. Immune responses and immunity to SARS-CoV-2, European Centre for Disease Prevention and Control. 2020. https:\/\/www.ecdc.europa.eu\/en\/covid-19\/latest-evidence\/immune-responses. Accessed 30 Nov 2020."},{"issue":"18","key":"499_CR44","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","volume":"383","author":"DF Gudbjartsson","year":"2020","unstructured":"Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"499_CR45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine T, Perez-Potti A, Rivera-Ballesteros O, Str\u00e5lin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158-68.e14.","journal-title":"Cell"},{"key":"499_CR46","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1056\/NEJMpv2035709","volume":"384","author":"JA Barocas","year":"2020","unstructured":"Barocas JA. Business not as usual\u2014Covid-19 vaccination in persons with substance use disorders. N Engl J Med. 2020;384:e6.","journal-title":"N Engl J Med"},{"issue":"11","key":"499_CR47","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2105\/AJPH.91.11.1791","volume":"91","author":"DC Des Jarlais","year":"2001","unstructured":"Des Jarlais DC, Fisher DG, Newman JC, Trubatch BN, Yancovitz M, Paone D, et al. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program. Am J Public Health. 2001;91(11):1791\u20132.","journal-title":"Am J Public Health"},{"issue":"3","key":"499_CR48","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0740-5472(99)00064-1","volume":"18","author":"S Stancliff","year":"2000","unstructured":"Stancliff S, Salomon N, Perlman DC, Russell PC. Provision of influenza and pneumococcal vaccines to injection drug users at a syringe exchange. J Subst Abuse Treat. 2000;18(3):263\u20135.","journal-title":"J Subst Abuse Treat"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00499-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T22:03:47Z","timestamp":1620684227000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00499-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["499"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00499-z","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"6 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants were informed about the aims of the study and provided signed informed consent before inclusion in the study. The study was performed in accordance with the Helsinki Declaration and was approved by The Regional Ethical Review Board in Stockholm (Dnr: 2013\/495-31\/3, 2015\/1374-32 and 2020-03325).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KL, CW, EH and AH have no conflict of interest. MK has received honoraria for lectures\/consultancy from AbbVie, Gilead, MSD, Mundipharma, DnE Pharma and Nordic Drugs, and has received research grants from Gilead and Nordic Drugs.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}